In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immatics (IMTX – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $9.97.
According to TipRanks, Suvannavejh is a 3-star analyst with an average return of 3.6% and a 49.42% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Bioxcel Therapeutics, and Cerevel Therapeutics Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $18.25 average price target, which is an 83.05% upside from current levels. In a report released on May 16, Jefferies also maintained a Buy rating on the stock with a $20.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $13.60 and a one-year low of $5.85. Currently, Immatics has an average volume of 380.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
Read More on IMTX:
- Immatics Announces First Quarter 2023 Financial Results and Business Update
- Immatics N.V. (IMTX) Q1 Earnings Cheat Sheet
- Immatics Soars after Positive Clinical Update
- Immatics reports interim clinical data from ongoing Phase 1b Cohort A
- Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
